Mid-Term Outcomes of a Novel TAVR Device for Pure Aortic Regurgitation
JACC: Cardiovascular Interventions · 2025-12 · 18 (24) · 3040-3051
DOI: 10.1016/j.jcin.2025.10.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-12. Verfasst von Bowen Xiao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China; Cardiovascular Research …. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve Insufficiency, Aortic Valve, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Sichuan University West China Hospital.
Abstract (Originalsprache)
BACKGROUND: Patients with severe aortic regurgitation (AR) frequently face high surgical risks, rendering them ineligible for surgery. Transcatheter aortic valve replacement (TAVR) is now a primary therapy for aortic valve stenosis. However, its application in pure native AR has been relatively limited. OBJECTIVES: The aim of this study was to evaluate the mid-term efficacy and safety of a novel self-expanding transfemoral TAVR device designed for treating pure native AR. METHODS: A prospective, single-arm clinical trial (ChiCTR2300075152) enrolled 110 consecutive patients with severe pure AR from 15 centers. The Pioneer Valve system with a rotatable feature and 3 independently angle-adjustable locators was used. Outcomes up to 1-year follow-up were reported per Valve Academic Research Consortium 3 criteria. The median clinical follow-up duration was 348 days (Q1-Q3: 342-357 days). RESULTS: The mean age was 73.37 ± 4.21 years, with a median Society of Thoracic Surgeons score of 5.97% (Q1-Q3: 4.04%-8.63%). Technical success was achieved in 109 of 110 cases (99.1%), and valve migration occurred in 1 case. Mean aortic valve gradient and mean effective orifice area at 30 days were 7.88 ± 2.7 mm Hg and 2.2 ± 0.64 cm2, respectively. New permanent pacemaker implantation occurred in 23 of 105 cases (21.9%; 95% CI: 14.3%-29.8%). All-cause mortality was 3 of 110 (2.7%; 95% CI: 0.9%-8.3%) at 1 year. Significant improvements in NYHA functional class, Kansas City Cardiomyopathy Questionnaire score, and positive left ventricular remodeling were observed up to 1 year. CONCLUSIONS: This study demonstrates that the Pioneer Valve provides a safe and effective alternative for high-risk or inoperable patients with severe pure AR, achieving favorable mid-term outcomes with stable hemodynamic performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China; Cardiovascular Research Laboratory, West China Hospital/West China School of Medicine, Sichuan…
- Department of Cardiology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Cardiovascular Medicine, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, China.
- Department of Cardiovascular Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China.
- Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Förderung
- Sichuan University West China Hospital
Zitieren
APA
Xiao, B., Liu, L., Guo, Y., Liu, J., Yang, P., Xiao, Y., Xiu, J., Zhang, J., Fang, Z., Zhang, G., Jiang, H., Liu, J., Liu, X., Shen, Y., Yang, J., Zhang, H., Shi, J., Ye, J., & Guo, Y. (2025). Mid-Term Outcomes of a Novel TAVR Device for Pure Aortic Regurgitation. JACC: Cardiovascular Interventions, 18(24), 3040-3051. https://doi.org/10.1016/j.jcin.2025.10.017
Vancouver
Xiao B, Liu L, Guo Y, Liu J, Yang P, Xiao Y, et al. Mid-Term Outcomes of a Novel TAVR Device for Pure Aortic Regurgitation. JACC: Cardiovascular Interventions. 2025;18(24):3040-3051. doi:10.1016/j.jcin.2025.10.017
BibTeX
@article{Xiao2025,
author = {Xiao, Bowen and Liu, Lulu and Guo, Yansong and Liu, Jian and Yang, Pengwei and Xiao, Yingbin and Xiu, Jiancheng and Zhang, Junjie and Fang, Zhenfei and Zhang, Gejun and Jiang, Hong and Liu, Jinping and Liu, Xianbao and Shen, Yangyang and Yang, Jian and Zhang, Haibo and Shi, Jun and Ye, Jian and Guo, Yingqiang},
title = {Mid-Term Outcomes of a Novel TAVR Device for Pure Aortic Regurgitation},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {24},
pages = {3040--3051},
doi = {10.1016/j.jcin.2025.10.017}
}
EUVIMED